JP2024507717A5 - - Google Patents
Info
- Publication number
- JP2024507717A5 JP2024507717A5 JP2023547237A JP2023547237A JP2024507717A5 JP 2024507717 A5 JP2024507717 A5 JP 2024507717A5 JP 2023547237 A JP2023547237 A JP 2023547237A JP 2023547237 A JP2023547237 A JP 2023547237A JP 2024507717 A5 JP2024507717 A5 JP 2024507717A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- premrna
- item
- approximately
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163145288P | 2021-02-03 | 2021-02-03 | |
| US63/145,288 | 2021-02-03 | ||
| PCT/US2022/015074 WO2022169947A2 (en) | 2021-02-03 | 2022-02-03 | Compositions for treatment of conditions and diseases associated with polycystin expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507717A JP2024507717A (ja) | 2024-02-21 |
| JP2024507717A5 true JP2024507717A5 (https=) | 2025-02-12 |
Family
ID=82741748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547237A Pending JP2024507717A (ja) | 2021-02-03 | 2022-02-03 | ポリシスチン発現に関連する状態及び疾患の治療のための組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240117353A1 (https=) |
| EP (1) | EP4288543A4 (https=) |
| JP (1) | JP2024507717A (https=) |
| KR (1) | KR20230150973A (https=) |
| CN (1) | CN117413061A (https=) |
| AR (1) | AR124809A1 (https=) |
| AU (1) | AU2022215577A1 (https=) |
| BR (1) | BR112023015636A2 (https=) |
| CA (1) | CA3207341A1 (https=) |
| MX (1) | MX2023009151A (https=) |
| TW (1) | TW202242113A (https=) |
| WO (1) | WO2022169947A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4612295A1 (en) * | 2022-10-31 | 2025-09-10 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6916619B2 (en) * | 2001-10-12 | 2005-07-12 | Athena Diagnostics, Inc. | Compositions and methods for genetic analysis of polycystic kidney disease |
| US11096956B2 (en) * | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| JP2018538287A (ja) * | 2015-12-14 | 2018-12-27 | コールド スプリング ハーバー ラボラトリー | 多発性嚢胞腎の処置のためのアンチセンスオリゴマー |
| HUE070436T2 (hu) * | 2017-10-23 | 2025-06-28 | Stoke Therapeutics Inc | Antiszensz oligomerek nonszensz-mediált RNS-lebomláson alapuló állapotok és betegségek kezelésére |
-
2022
- 2022-02-03 CN CN202280019548.3A patent/CN117413061A/zh active Pending
- 2022-02-03 AU AU2022215577A patent/AU2022215577A1/en active Pending
- 2022-02-03 BR BR112023015636A patent/BR112023015636A2/pt unknown
- 2022-02-03 WO PCT/US2022/015074 patent/WO2022169947A2/en not_active Ceased
- 2022-02-03 KR KR1020237029596A patent/KR20230150973A/ko active Pending
- 2022-02-03 JP JP2023547237A patent/JP2024507717A/ja active Pending
- 2022-02-03 CA CA3207341A patent/CA3207341A1/en active Pending
- 2022-02-03 MX MX2023009151A patent/MX2023009151A/es unknown
- 2022-02-03 AR ARP220100222A patent/AR124809A1/es unknown
- 2022-02-03 EP EP22750375.2A patent/EP4288543A4/en active Pending
- 2022-02-07 TW TW111104414A patent/TW202242113A/zh unknown
-
2023
- 2023-08-02 US US18/364,244 patent/US20240117353A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220267765A1 (en) | Treatment of genetic disorders associated with dna repeat instability | |
| US6653467B1 (en) | Medicament for treatment of Duchenne muscular dystrophy | |
| JP2024045199A5 (https=) | ||
| GB2584204A (en) | Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases | |
| JP2018538288A5 (https=) | ||
| JP2022544702A5 (https=) | ||
| JP2019501892A5 (https=) | ||
| JP2018538287A5 (https=) | ||
| TW201831686A (zh) | α-1抗胰蛋白酶 (AAT) RNAi 藥劑、包含AAT RNAi 藥劑之組合物及使用方法 | |
| CN108368506A (zh) | 用于抑制lpa的基因表达的组合物和方法 | |
| JP2011510678A (ja) | Ｄｎａ反復不安定性関連遺伝性障害を治療するための方法及び手段 | |
| JP2017519766A5 (https=) | ||
| JP2019500347A5 (https=) | ||
| JP2023514570A5 (https=) | ||
| CN101501193A (zh) | 用于治疗与dna重复不稳定性相关的遗传病的方法和手段 | |
| JP2024079818A (ja) | コレステリルエステル蓄積症の処置のための方法及び組成物 | |
| EP1185637B1 (en) | Antisense to c-myc for treatment of polycystic kidney disease | |
| US20240254488A1 (en) | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases | |
| JP2024507717A5 (https=) | ||
| JP2021523227A5 (https=) | ||
| JP2022532998A5 (https=) | ||
| JP2021529758A (ja) | 麻酔誘発性神経毒性の処置のための組成物及び方法 | |
| WO2024092226A1 (en) | Compositions and methods for targeting a splice variant of the regulatory subunit of myosin phosphatase (mp) for therapeutic gain in hypertension and heart failure | |
| JP2025534850A (ja) | ナンセンス介在ｒｎａ分解による状態および疾患の治療のためのアンチセンスオリゴマー | |
| BR112020018715A2 (pt) | Terapia de combinação para amiloidose associada a ttr |